<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:59:00 -0700</creation_date>
  <update_date>2013-01-15 19:59:00 -0700</update_date>
  <accession>HMDBP07433</accession>
  <secondary_accessions>
    <accession>13141</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>Alpha-1A adrenoceptor</synonym>
    <synonym>Alpha-1A adrenoreceptor</synonym>
    <synonym>Alpha-1C adrenergic receptor</synonym>
    <synonym>Alpha-adrenergic receptor 1c</synonym>
  </synonyms>
  <gene_name>ADRA1A</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00464</accession>
      <name>Calcium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02182</accession>
      <name>Phenylephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00216</accession>
      <name>Norepinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01942</accession>
      <name>Phenylpropanolamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01943</accession>
      <name>Pseudoephedrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00068</accession>
      <name>Epinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05020</accession>
      <name>Risperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14356</accession>
      <name>Midodrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14391</accession>
      <name>Ziprasidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14443</accession>
      <name>Dapiprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14490</accession>
      <name>Alfuzosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13938</accession>
      <name>Promazine 5-sulfoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14592</accession>
      <name>Dipivefrin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14593</accession>
      <name>Droperidol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14600</accession>
      <name>Prazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14620</accession>
      <name>Chlorpromazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14680</accession>
      <name>Nortriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14683</accession>
      <name>Amoxapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14728</accession>
      <name>Doxazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14736</accession>
      <name>Labetalol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14748</accession>
      <name>Metaraminol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14760</accession>
      <name>Nicardipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14794</accession>
      <name>Trazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14817</accession>
      <name>Thioridazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14830</accession>
      <name>Phentolamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14834</accession>
      <name>Ergotamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14837</accession>
      <name>Nicergoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14844</accession>
      <name>Tamsulosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14861</accession>
      <name>Methoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14864</accession>
      <name>Trimipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14889</accession>
      <name>Epinastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14915</accession>
      <name>Propiomazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14935</accession>
      <name>Tolazoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14969</accession>
      <name>Trifluoperazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15003</accession>
      <name>Benzphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15013</accession>
      <name>Flupenthixol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15061</accession>
      <name>Phenoxybenzamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15069</accession>
      <name>Maprotiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15070</accession>
      <name>Oxymetazoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15099</accession>
      <name>Apraclonidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15183</accession>
      <name>Ergoloid mesylate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15202</accession>
      <name>Promethazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13946</accession>
      <name>8-Hydroxycarvedilol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15273</accession>
      <name>Doxepin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15280</accession>
      <name>Nefazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15282</accession>
      <name>Desipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15293</accession>
      <name>Terazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15317</accession>
      <name>Pergolide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15331</accession>
      <name>Bromocriptine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05042</accession>
      <name>Aripiprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15383</accession>
      <name>Ergonovine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15396</accession>
      <name>Paliperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15404</accession>
      <name>Dihydroergotoxine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15409</accession>
      <name>Bevantolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15451</accession>
      <name>Ephedrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15452</accession>
      <name>Mephentermine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15474</accession>
      <name>Methotrimeprazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15516</accession>
      <name>Dextroamphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15519</accession>
      <name>Phendimetrazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15552</accession>
      <name>Acepromazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15559</accession>
      <name>Thioproperazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15561</accession>
      <name>Zuclopenthixol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15618</accession>
      <name>Sertindole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15627</accession>
      <name>Droxidopa</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15640</accession>
      <name>Xylometazoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15651</accession>
      <name>Isometheptene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15652</accession>
      <name>Levonordefrin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15656</accession>
      <name>Naphazoline</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>molecular transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>signal transducer activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>g-protein coupled amine receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>alpha-adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>alpha1-adrenergic receptor activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:8</chromosome_location>
    <locus>8p21.2</locus>
    <gene_sequence>&gt;1401 bp
ATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG
GTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG
GTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC
ACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG
CCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC
ATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC
TCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG
AGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA
CCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG
GAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC
CTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT
GGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC
GCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG
CTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC
TTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT
TTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC
ATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC
TTGAGAATCCAGTGTCTCTGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG
CACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA
TCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC
TCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC
ACAGCCCGGGTGAGAAGTAAAAGCTTTTTGCAGGTCTGCTGCTGTGTAGGGCCCTCAACC
CCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT
GAGAACGGGGAGGAAGTCTAG</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>466</residue_number>
    <molecular_weight>51486.0</molecular_weight>
    <theoretical_pi>9.23</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>28-51</region>
      <region>65-88</region>
      <region>100-122</region>
      <region>144-167</region>
      <region>182-205</region>
      <region>274-297</region>
      <region>306-329</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Alpha-1A adrenergic receptor
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV
THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII
SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE
EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN
APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD
FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL
HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT
TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV</protein_sequence>
  </protein_properties>
  <genbank_protein_id>21928677</genbank_protein_id>
  <uniprot_id>P35348</uniprot_id>
  <uniprot_name>ADA1A_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>AB065703</genbank_gene_id>
  <genecard_id>ADRA1A</genecard_id>
  <geneatlas_id>ADRA1A</geneatlas_id>
  <hgnc_id>HGNC:277</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Hirasawa A, Horie K, Tanaka T, Takagaki K, Murai M, Yano J, Tsujimoto G: Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor. Biochem Biophys Res Commun. 1993 Sep 15;195(2):902-9.</reference_text>
      <pubmed_id>8396931</pubmed_id>
    </reference>
    <reference>
      <reference_text>Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M: Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c. Biochem Biophys Res Commun. 1994 Jun 30;201(3):1296-304.</reference_text>
      <pubmed_id>8024574</pubmed_id>
    </reference>
    <reference>
      <reference_text>Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.</reference_text>
      <pubmed_id>8183249</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tseng-Crank J, Kost T, Goetz A, Hazum S, Roberson KM, Haizlip J, Godinot N, Robertson CN, Saussy D: The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Br J Pharmacol. 1995 Aug;115(8):1475-85.</reference_text>
      <pubmed_id>8564208</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hirasawa A, Shibata K, Horie K, Takei Y, Obika K, Tanaka T, Muramoto N, Takagaki K, Yano J, Tsujimoto G: Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants. FEBS Lett. 1995 Apr 24;363(3):256-60.</reference_text>
      <pubmed_id>7737411</pubmed_id>
    </reference>
    <reference>
      <reference_text>Schwinn DA, Johnston GI, Page SO, Mosley MJ, Wilson KH, Worman NP, Campbell S, Fidock MD, Furness LM, Parry-Smith DJ, et al.: Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42.</reference_text>
      <pubmed_id>7815325</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chang DJ, Chang TK, Yamanishi SS, Salazar FH, Kosaka AH, Khare R, Bhakta S, Jasper JR, Shieh IS, Lesnick JD, Ford AP, Daniels DV, Eglen RM, Clarke DE, Bach C, Chan HW: Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms. FEBS Lett. 1998 Jan 30;422(2):279-83.</reference_text>
      <pubmed_id>9490024</pubmed_id>
    </reference>
    <reference>
      <reference_text>Coge F, Guenin SP, Renouard-Try A, Rique H, Ouvry C, Fabry N, Beauverger P, Nicolas JP, Galizzi JP, Boutin JA, Canet E: Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human alpha1A-adrenoceptors. Biochem J. 1999 Oct 1;343 Pt 1:231-9.</reference_text>
      <pubmed_id>10493934</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605.</reference_text>
      <pubmed_id>8196478</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S, Tsujimoto G: Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br J Pharmacol. 1996 Jul;118(6):1403-8.</reference_text>
      <pubmed_id>8832064</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sofowora GG, Dishy V, Landau R, Xie HG, Prasad HC, Byrne DW, Smiley RM, Kim RB, Wood AJ, Stein CM: Alpha 1A-adrenergic receptor polymorphism and vascular response.  Clin Pharmacol Ther. 2004 Jun;75(6):539-45.</reference_text>
      <pubmed_id>15179408</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Lachnit WG, Tran AM, Clarke DE, Ford AP: Pharmacological characterization of an alpha 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat. Br J Pharmacol. 1997 Mar;120(5):819-26.</reference_text>
        <pubmed_id>9138687</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Burt RP, Chapple CR, Marshall I: The role of diacylglycerol and activation of protein kinase C in alpha 1A-adrenoceptor-mediated contraction to noradrenaline of rat isolated epididymal vas deferens. Br J Pharmacol. 1996 Jan;117(1):224-30.</reference_text>
        <pubmed_id>8825367</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norepinephrine</name>
        <accession>HMDB00216</accession>
      </metabolite>
      <reference>
        <reference_text>Bishop MJ: Recent advances in the discovery of alpha1-adrenoceptor agonists.  Curr Top Med Chem. 2007;7(2):135-45.</reference_text>
        <pubmed_id>17266602</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midodrine</name>
        <accession>HMDB14356</accession>
      </metabolite>
      <reference>
        <reference_text>Buckner SA, Milicic I, Daza AV, Meyer MD, Altenbach RJ, Williams M, Sullivan JP, Brioni JD: ABT-866, a novel alpha(1A)-adrenoceptor agonist with antagonist properties at the alpha(1B)- and alpha(1D)-adrenoceptor subtypes. Eur J Pharmacol. 2002 Aug 2;449(1-2):159-65.</reference_text>
        <pubmed_id>12163120</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midodrine</name>
        <accession>HMDB14356</accession>
      </metabolite>
      <reference>
        <reference_text>Taniguchi N, Hamada K, Ogasawara T, Ukai Y, Yoshikuni Y, Kimura K: NS-49, an alpha 1A-adrenoceptor agonist, selectively increases intraurethral pressure in dogs. Eur J Pharmacol. 1996 Dec 27;318(1):117-22.</reference_text>
        <pubmed_id>9007522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midodrine</name>
        <accession>HMDB14356</accession>
      </metabolite>
      <reference>
        <reference_text>Altenbach RJ, Khilevich A, Kolasa T, Rohde JJ, Bhatia PA, Patel MV, Searle XB, Yang F, Bunnelle WH, Tietje K, Bayburt EK, Carroll WA, Meyer MD, Henry R, Buckner SA, Kuk J, Daza AV, Milicic IV, Cain JC, Kang CH, Ireland LM, Carr TL, Miller TR, Hancock AA, Nakane M, Esbenshade TA, Brune ME, O'Neill AB, Gauvin DM, Katwala SP, Holladay MW, Brioni JD, Sullivan JP: Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem. 2004 Jun 3;47(12):3220-35.</reference_text>
        <pubmed_id>15163201</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E: Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity.  J Clin Psychopharmacol. 2010 Feb;30(1):68-71.</reference_text>
        <pubmed_id>20075651</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dapiprazole</name>
        <accession>HMDB14443</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dapiprazole</name>
        <accession>HMDB14443</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dapiprazole</name>
        <accession>HMDB14443</accession>
      </metabolite>
      <reference>
        <reference_text>Eltze M: Affinity of the miotic drug, dapiprazole, at alpha 1-adrenoceptor subtypes A, B and D. J Pharm Pharmacol. 1997 Nov;49(11):1091-5.</reference_text>
        <pubmed_id>9401944</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8.</reference_text>
        <pubmed_id>8799556</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Lee M: Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.  Am J Health Syst Pharm. 2003 Jul 15;60(14):1426-39.</reference_text>
        <pubmed_id>12892027</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity.  Prostate. 1997 Feb 15;30(3):202-15.</reference_text>
        <pubmed_id>9122046</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13.</reference_text>
        <pubmed_id>15639685</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther. 1997 Jul;282(1):228-35.</reference_text>
        <pubmed_id>9223558</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605.</reference_text>
        <pubmed_id>8196478</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Beique L, Por CP, Evans MF: Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia? Can Fam Physician. 1998 Dec;44:2659-62.</reference_text>
        <pubmed_id>9870119</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>McVary KT: BPH: epidemiology and comorbidities.  Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8.</reference_text>
        <pubmed_id>16613526</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96.</reference_text>
        <pubmed_id>16553574</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4.</reference_text>
        <pubmed_id>11750253</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipivefrin</name>
        <accession>HMDB14592</accession>
      </metabolite>
      <reference>
        <reference_text>Sanbe A, Tanaka Y, Fujiwara Y, Tsumura H, Yamauchi J, Cotecchia S, Koike K, Tsujimoto G, Tanoue A: Alpha1-adrenoceptors are required for normal male sexual function.  Br J Pharmacol. 2007 Oct;152(3):332-40. Epub 2007 Jul 2.</reference_text>
        <pubmed_id>17603545</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipivefrin</name>
        <accession>HMDB14592</accession>
      </metabolite>
      <reference>
        <reference_text>Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y: Expressions and mechanical functions of alpha1-adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5. Epub 2007 Jul 6.</reference_text>
        <pubmed_id>17658513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droperidol</name>
        <accession>HMDB14593</accession>
      </metabolite>
      <reference>
        <reference_text>Zupko I, Janossy K, Maul K, Marki A, Falkay G: Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102.</reference_text>
        <pubmed_id>12505540</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Chang HK, Hsu FL, Liu IM, Cheng JT: Stimulatory effect of cinnamic acid analogues on alpha1A-adrenoceptors in-vitro.  J Pharm Pharmacol. 2003 Jun;55(6):833-7.</reference_text>
        <pubmed_id>12841945</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73.</reference_text>
        <pubmed_id>8925876</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Morris DP, Price RR, Smith MP, Lei B, Schwinn DA: Cellular trafficking of human alpha1a-adrenergic receptors is continuous and primarily agonist-independent. Mol Pharmacol. 2004 Oct;66(4):843-54. Epub 2004 Jul 16.</reference_text>
        <pubmed_id>15258254</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10.</reference_text>
        <pubmed_id>7691623</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki Y, Kanada A, Okaya Y, Aisaka K: Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. Eur J Pharmacol. 2000 Apr 7;394(1):123-30.</reference_text>
        <pubmed_id>10771044</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Tomiyama Y, Kobayashi K, Tadachi M, Kobayashi S, Inada Y, Kobayashi M, Yamazaki Y: Expressions and mechanical functions of alpha1-adrenoceptor subtypes in hamster ureter. Eur J Pharmacol. 2007 Nov 14;573(1-3):201-5. Epub 2007 Jul 6.</reference_text>
        <pubmed_id>17658513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Zacharia J, Hillier C, MacDonald A: Alpha1-adrenoceptor subtypes involved in vasoconstrictor responses to exogenous and neurally released noradrenaline in rat femoral resistance arteries. Br J Pharmacol. 2004 Mar;141(6):915-24. Epub 2004 Feb 23.</reference_text>
        <pubmed_id>14980979</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat.  Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4.</reference_text>
        <pubmed_id>15695070</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. Epub 2010 Apr 2.</reference_text>
        <pubmed_id>20363235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxapine</name>
        <accession>HMDB14683</accession>
      </metabolite>
      <reference>
        <reference_text>Wei HB, Niu XY: [Comparison of the affinities of amoxapine and loxapine for various receptors in rat brain and the receptor down-regulation after chronic administration]. Yao Xue Xue Bao. 1990;25(12):881-5.</reference_text>
        <pubmed_id>1966571</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amoxapine</name>
        <accession>HMDB14683</accession>
      </metabolite>
      <reference>
        <reference_text>Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81.</reference_text>
        <pubmed_id>9589848</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Yono M, Foster HE Jr, Shin D, Takahashi W, Pouresmail M, Latifpour J: Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol. 2004 Oct;82(10):872-8.</reference_text>
        <pubmed_id>15573147</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.</reference_text>
        <pubmed_id>8736427</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35.</reference_text>
        <pubmed_id>14767264</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Ishizuka O, Pandita RK, Mattiasson A, Steers WD, Andersson KE: Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):787-93.</reference_text>
        <pubmed_id>9205965</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Bae JH, Jung PB, Lee JG: The effects of alpha-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. BJU Int. 2005 Nov;96(7):1131-5.</reference_text>
        <pubmed_id>16225542</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia.  Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.</reference_text>
        <pubmed_id>19002123</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology.  Am Heart J. 2006 Nov;152(5):842-50.</reference_text>
        <pubmed_id>17070143</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists.  Eur Urol. 1999;36 Suppl 1:35-41; discussion 65.</reference_text>
        <pubmed_id>10393471</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Sassard J, Zech PY, Pozet N, Cuisinaud G, Vincent M: [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]. J Pharmacol. 1983;14 Suppl 2:121-9.</reference_text>
        <pubmed_id>6355664</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Pedersen ME, Cockcroft JR: The vasodilatory beta-blockers.  Curr Hypertens Rep. 2007 Aug;9(4):269-77.</reference_text>
        <pubmed_id>17686376</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5.</reference_text>
        <pubmed_id>1358746</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>Rosendorff C: Beta-blocking agents with vasodilator activity.  J Hypertens Suppl. 1993 Jun;11(4):S37-40.</reference_text>
        <pubmed_id>8104240</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Labetalol</name>
        <accession>HMDB14736</accession>
      </metabolite>
      <reference>
        <reference_text>van Zwieten PA: An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists. Drugs. 1993 Apr;45(4):509-17.</reference_text>
        <pubmed_id>7684671</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metaraminol</name>
        <accession>HMDB14748</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metaraminol</name>
        <accession>HMDB14748</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metaraminol</name>
        <accession>HMDB14748</accession>
      </metabolite>
      <reference>
        <reference_text>Tatsuta M, Iishi H, Baba M, Yano H, Sakai N, Uehara H, Hirasawa R, Nakaizumi A: Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1998 Jul 29;77(3):467-9.</reference_text>
        <pubmed_id>9663612</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Thayer SA, Welcome M, Chhabra A, Fairhurst AS: Effects of dihydropyridine calcium channel blocking drugs on rat brain muscarinic and alpha-adrenergic receptors. Biochem Pharmacol. 1985 Jan 15;34(2):175-80.</reference_text>
        <pubmed_id>2981533</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trazodone</name>
        <accession>HMDB14794</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thioridazine</name>
        <accession>HMDB14817</accession>
      </metabolite>
      <reference>
        <reference_text>Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10.</reference_text>
        <pubmed_id>7691623</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thioridazine</name>
        <accession>HMDB14817</accession>
      </metabolite>
      <reference>
        <reference_text>Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat.  Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4.</reference_text>
        <pubmed_id>15695070</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentolamine</name>
        <accession>HMDB14830</accession>
      </metabolite>
      <reference>
        <reference_text>Giussani DA, Moore PJ, Bennet L, Spencer JA, Hanson MA: Alpha 1- and alpha 2-adrenoreceptor actions of phentolamine and prazosin on breathing movements in fetal sheep in utero. J Physiol. 1995 Jul 1;486 ( Pt 1):249-55.</reference_text>
        <pubmed_id>7562640</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentolamine</name>
        <accession>HMDB14830</accession>
      </metabolite>
      <reference>
        <reference_text>Bylund DB: Subtypes of alpha 1- and alpha 2-adrenergic receptors.  FASEB J. 1992 Feb 1;6(3):832-9.</reference_text>
        <pubmed_id>1346768</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phentolamine</name>
        <accession>HMDB14830</accession>
      </metabolite>
      <reference>
        <reference_text>Saeed M, Sommer O, Holtz J, Bassenge E: Alpha-adrenoceptor blockade by phentolamine causes beta-adrenergic vasodilation by increased catecholamine release due to presynaptic alpha-blockade. J Cardiovasc Pharmacol. 1982 Jan-Feb;4(1):44-52.</reference_text>
        <pubmed_id>6176798</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Gornemann T, Jahnichen S, Schurad B, Latte KP, Horowski R, Tack J, Flieger M, Pertz HH: Pharmacological properties of a wide array of ergolines at functional alpha(1)-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jan;376(5):321-30. Epub 2007 Dec 8.</reference_text>
        <pubmed_id>18066532</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicergoline</name>
        <accession>HMDB14837</accession>
      </metabolite>
      <reference>
        <reference_text>Alvarez-Guerra M, Bertholom N, Garay RP: Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha 1A-adrenoceptor subtype in the rat. Fundam Clin Pharmacol. 1999;13(1):50-8.</reference_text>
        <pubmed_id>10027088</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Abrams P, Speakman M, Stott M, Arkell D, Pocock R: A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol. 1997 Oct;80(4):587-96.</reference_text>
        <pubmed_id>9352698</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304.</reference_text>
        <pubmed_id>10503165</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11.</reference_text>
        <pubmed_id>9352700</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AF, Abrams P: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):155-67.</reference_text>
        <pubmed_id>8647141</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ: Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol. 1996;29(2):145-54.</reference_text>
        <pubmed_id>8647140</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Chen Y, Li H, Dong Q, Wang KJ: Blockade of alpha 1A-adrenoceptor: a novel possible strategy for male contraception. Med Hypotheses. 2009 Aug;73(2):140-1. Epub 2009 May 8.</reference_text>
        <pubmed_id>19427736</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Michel MC, de la Rosette JJ: Efficacy and safety of tamsulosin in the treatment of urological diseases.  Expert Opin Pharmacother. 2004 Jan;5(1):151-60.</reference_text>
        <pubmed_id>14680444</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methoxamine</name>
        <accession>HMDB14861</accession>
      </metabolite>
      <reference>
        <reference_text>Satoh M, Kojima C, Kokubu N, Takayanagi I: Alpha 1-adrenoceptor subtypes mediating the regulation and modulation of Ca2+ sensitization in rabbit thoracic aorta. Eur J Pharmacol. 1994 Nov 24;265(3):133-9.</reference_text>
        <pubmed_id>7875228</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methoxamine</name>
        <accession>HMDB14861</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki E, Tsujimoto G, Tamura K, Hashimoto K: Two pharmacologically distinct alpha 1-adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role. Mol Pharmacol. 1990 Nov;38(5):725-36.</reference_text>
        <pubmed_id>1978244</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methoxamine</name>
        <accession>HMDB14861</accession>
      </metabolite>
      <reference>
        <reference_text>Piascik MT, Sparks MS, Pruitt TA, Soltis EE: Evidence for a complex interaction between the subtypes of the alpha 1-adrenoceptor. Eur J Pharmacol. 1991 Jul 9;199(3):279-89.</reference_text>
        <pubmed_id>1680715</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methoxamine</name>
        <accession>HMDB14861</accession>
      </metabolite>
      <reference>
        <reference_text>Sattar MA, Johns EJ: Evidence for an alpha 1-adrenoceptor subtype mediating adrenergic vasoconstriction in Wistar normotensive and stroke-prone spontaneously hypertensive rat kidney. J Cardiovasc Pharmacol. 1994 Feb;23(2):232-9.</reference_text>
        <pubmed_id>7511752</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methoxamine</name>
        <accession>HMDB14861</accession>
      </metabolite>
      <reference>
        <reference_text>Hoang TV, Choe EU, Burgess RS, Cork RC, Flint LM, Ferrara JJ: Characterization of alpha-adrenoceptor activity in the preterm piglet mesentery.  J Pediatr Surg. 1996 Dec;31(12):1659-62.</reference_text>
        <pubmed_id>8986981</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Berger M, Gastpar M: Trimipramine: a challenge to current concepts on antidepressives.  Eur Arch Psychiatry Clin Neurosci. 1996;246(5):235-9.</reference_text>
        <pubmed_id>8863001</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Epinastine</name>
        <accession>HMDB14889</accession>
      </metabolite>
      <reference>
        <reference_text>Dupont LJ, Meade CJ, Demedts MG, Verleden GM: Epinastine (WAL 801CL) modulates the noncholinergic contraction in guinea-pig airways in vitro by a prejunctional 5-HT1-like receptor. Eur Respir J. 1996 Jul;9(7):1433-8.</reference_text>
        <pubmed_id>8836655</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propiomazine</name>
        <accession>HMDB14915</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolazoline</name>
        <accession>HMDB14935</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolazoline</name>
        <accession>HMDB14935</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolazoline</name>
        <accession>HMDB14935</accession>
      </metabolite>
      <reference>
        <reference_text>Teskin O, Uydes-Dogan BS, Enc Y, Alp FI, Kaleli D, Keser S, Iyigun T, Bilgen F, Dagsali S, Ozdemir O: Comparative effects of tolazoline and nitroprusside on human isolated radial artery. Ann Thorac Surg. 2006 Jan;81(1):125-31.</reference_text>
        <pubmed_id>16368348</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolazoline</name>
        <accession>HMDB14935</accession>
      </metabolite>
      <reference>
        <reference_text>Song W, Zhang Y, Xia L, Liu G: [Effects of some mexiletine derivatives on alpha 1-adrenoceptors].  Yao Xue Xue Bao. 1998;33(2):102-5.</reference_text>
        <pubmed_id>11938943</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoperazine</name>
        <accession>HMDB14969</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoperazine</name>
        <accession>HMDB14969</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoperazine</name>
        <accession>HMDB14969</accession>
      </metabolite>
      <reference>
        <reference_text>Fujinaga M, Hoffman BB, Baden JM: Receptor subtype and intracellular signal transduction pathway associated with situs inversus induced by alpha 1 adrenergic stimulation in rat embryos. Dev Biol. 1994 Apr;162(2):558-67.</reference_text>
        <pubmed_id>8150214</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoperazine</name>
        <accession>HMDB14969</accession>
      </metabolite>
      <reference>
        <reference_text>Huerta-Bahena J, Villalobos-Molina R, Garcia-Sainz JA: Trifluoperazine and chlorpromazine antagonize alpha 1- but not alpha2- adrenergic effects. Mol Pharmacol. 1983 Jan;23(1):67-70.</reference_text>
        <pubmed_id>6135146</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzphetamine</name>
        <accession>HMDB15003</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzphetamine</name>
        <accession>HMDB15003</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flupenthixol</name>
        <accession>HMDB15013</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flupenthixol</name>
        <accession>HMDB15013</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenoxybenzamine</name>
        <accession>HMDB15061</accession>
      </metabolite>
      <reference>
        <reference_text>Stam WB, Van der Graaf PH, Saxena PR: Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery.  Br J Pharmacol. 1999 Jun;127(3):661-70.</reference_text>
        <pubmed_id>10401556</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenoxybenzamine</name>
        <accession>HMDB15061</accession>
      </metabolite>
      <reference>
        <reference_text>Michel MC, Hanft G, Gross G: Functional studies on alpha 1-adrenoceptor subtypes mediating inotropic effects in rat right ventricle. Br J Pharmacol. 1994 Feb;111(2):539-46.</reference_text>
        <pubmed_id>7911719</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenoxybenzamine</name>
        <accession>HMDB15061</accession>
      </metabolite>
      <reference>
        <reference_text>Yu Y, Koss MC: Functional characterization of alpha-adrenoceptors mediating pupillary dilation in rats. Eur J Pharmacol. 2003 Jun 20;471(2):135-40.</reference_text>
        <pubmed_id>12818701</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenoxybenzamine</name>
        <accession>HMDB15061</accession>
      </metabolite>
      <reference>
        <reference_text>Salles J, Gascon S, Badia A: Sustained increase in rat myocardial alpha 1A-adrenoceptors induced by 6-hydroxydopamine treatment involves a decelerated receptor turnover. Naunyn Schmiedebergs Arch Pharmacol. 1996 Mar;353(4):408-16.</reference_text>
        <pubmed_id>8935707</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenoxybenzamine</name>
        <accession>HMDB15061</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki E, Tsujimoto G, Tamura K, Hashimoto K: Two pharmacologically distinct alpha 1-adrenoceptor subtypes in the contraction of rabbit aorta: each subtype couples with a different Ca2+ signalling mechanism and plays a different physiological role. Mol Pharmacol. 1990 Nov;38(5):725-36.</reference_text>
        <pubmed_id>1978244</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymetazoline</name>
        <accession>HMDB15070</accession>
      </metabolite>
      <reference>
        <reference_text>Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91.</reference_text>
        <pubmed_id>8894610</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymetazoline</name>
        <accession>HMDB15070</accession>
      </metabolite>
      <reference>
        <reference_text>Deplanne V, Galzin AM: Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. J Pharmacol Exp Ther. 1996 Aug;278(2):527-34.</reference_text>
        <pubmed_id>8768700</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymetazoline</name>
        <accession>HMDB15070</accession>
      </metabolite>
      <reference>
        <reference_text>Shibata K, Taketani K: [Excitatory effect of noradrenaline on rat airway parasympathetic ganglion neurons]. Fukuoka Igaku Zasshi. 2001 Nov;92(11):377-83.</reference_text>
        <pubmed_id>11774707</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymetazoline</name>
        <accession>HMDB15070</accession>
      </metabolite>
      <reference>
        <reference_text>Furukawa K, Rosario DJ, Smith DJ, Chapple CR, Uchiyama T, Chess-Williams R: Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens.  Br J Pharmacol. 1995 Sep;116(1):1605-10.</reference_text>
        <pubmed_id>8564226</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymetazoline</name>
        <accession>HMDB15070</accession>
      </metabolite>
      <reference>
        <reference_text>Gonzalez-Espinosa C, Romero-Avila MT, Mora-Rodriguez DM, Gonzalez-Espinosa D, Garcia-Sainz JA: Molecular cloning and functional expression of the guinea pig alpha(1a)-adrenoceptor. Eur J Pharmacol. 2001 Aug 31;426(3):147-55.</reference_text>
        <pubmed_id>11527538</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apraclonidine</name>
        <accession>HMDB15099</accession>
      </metabolite>
      <reference>
        <reference_text>Moodley AA, Spooner RB: Apraclonidine in the diagnosis of Horner's syndrome.  S Afr Med J. 2007 Jul;97(7):506-7.</reference_text>
        <pubmed_id>17824139</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apraclonidine</name>
        <accession>HMDB15099</accession>
      </metabolite>
      <reference>
        <reference_text>Mirzai H, Baser EF: Congenital Horner's syndrome and the usefulness of the apraclonidine test in its diagnosis. Indian J Ophthalmol. 2006 Sep;54(3):197-9.</reference_text>
        <pubmed_id>16921219</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apraclonidine</name>
        <accession>HMDB15099</accession>
      </metabolite>
      <reference>
        <reference_text>Sueke H, Chandna A: Using apraclonidine in diagnosing Horner syndrome in children.  Am J Ophthalmol. 2010 May;149(5):869; author reply 870.</reference_text>
        <pubmed_id>20399934</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apraclonidine</name>
        <accession>HMDB15099</accession>
      </metabolite>
      <reference>
        <reference_text>Kawasaki A, Borruat FX: False negative apraclonidine test in two patients with Horner syndrome.  Klin Monbl Augenheilkd. 2008 May;225(5):520-2.</reference_text>
        <pubmed_id>18454417</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apraclonidine</name>
        <accession>HMDB15099</accession>
      </metabolite>
      <reference>
        <reference_text>Watts P, Satterfield D, Lim MK: Adverse effects of apraclonidine used in the diagnosis of Horner syndrome in infants. J AAPOS. 2007 Jun;11(3):282-3.</reference_text>
        <pubmed_id>17572343</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apraclonidine</name>
        <accession>HMDB15099</accession>
      </metabolite>
      <reference>
        <reference_text>Chen PL, Hsiao CH, Chen JT, Lu DW, Chen WY: Efficacy of apraclonidine 0.5% in the diagnosis of Horner syndrome in pediatric patients under low or high illumination. Am J Ophthalmol. 2006 Sep;142(3):469-74.</reference_text>
        <pubmed_id>16935593</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Apraclonidine</name>
        <accession>HMDB15099</accession>
      </metabolite>
      <reference>
        <reference_text>Freedman KA, Brown SM: Topical apraclonidine in the diagnosis of suspected Horner syndrome.  J Neuroophthalmol. 2005 Jun;25(2):83-5.</reference_text>
        <pubmed_id>15937427</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergoloid mesylate</name>
        <accession>HMDB15183</accession>
      </metabolite>
      <reference>
        <reference_text>Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17.</reference_text>
        <pubmed_id>2869188</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Stahl SM: Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008 Dec;13(12):1027-38.</reference_text>
        <pubmed_id>19179941</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102.</reference_text>
        <pubmed_id>6086881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD: Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.  J Clin Psychiatry. 1995;56 Suppl 6:3-11.</reference_text>
        <pubmed_id>7649970</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65.</reference_text>
        <pubmed_id>7855217</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terazosin</name>
        <accession>HMDB15293</accession>
      </metabolite>
      <reference>
        <reference_text>Chapple CR: Medical therapy and quality of life.  Eur Urol. 1998;34 Suppl 2:10-7; discussion 46.</reference_text>
        <pubmed_id>9732824</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terazosin</name>
        <accession>HMDB15293</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terazosin</name>
        <accession>HMDB15293</accession>
      </metabolite>
      <reference>
        <reference_text>Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11.</reference_text>
        <pubmed_id>9352700</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terazosin</name>
        <accession>HMDB15293</accession>
      </metabolite>
      <reference>
        <reference_text>Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.</reference_text>
        <pubmed_id>8736427</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terazosin</name>
        <accession>HMDB15293</accession>
      </metabolite>
      <reference>
        <reference_text>Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304.</reference_text>
        <pubmed_id>10503165</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terazosin</name>
        <accession>HMDB15293</accession>
      </metabolite>
      <reference>
        <reference_text>Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35.</reference_text>
        <pubmed_id>14767264</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Lam YW: Clinical pharmacology of dopamine agonists.  Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S.</reference_text>
        <pubmed_id>10641988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aripiprazole</name>
        <accession>HMDB05042</accession>
      </metabolite>
      <reference>
        <reference_text>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</reference_text>
        <pubmed_id>17848919</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergonovine</name>
        <accession>HMDB15383</accession>
      </metabolite>
      <reference>
        <reference_text>Gibson A, Carvajal A: Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9.</reference_text>
        <pubmed_id>2897449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergonovine</name>
        <accession>HMDB15383</accession>
      </metabolite>
      <reference>
        <reference_text>Zhu F, Han B, Kumar P, Liu X, Ma X, Wei X, Huang L, Guo Y, Han L, Zheng C, Chen Y: Update of TTD: Therapeutic Target Database.  Nucleic Acids Res. 2010 Jan;38(Database issue):D787-91. Epub 2009 Nov 20.</reference_text>
        <pubmed_id>19933260</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Cohen LJ: Risperidone.  Pharmacotherapy. 1994 May-Jun;14(3):253-65.</reference_text>
        <pubmed_id>7524043</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73.</reference_text>
        <pubmed_id>8925876</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania.  CNS Drugs. 2005;19(5):429-44.</reference_text>
        <pubmed_id>15907153</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52.</reference_text>
        <pubmed_id>15992090</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone.  Psychopharmacology (Berl). 1994 Feb;114(1):9-23.</reference_text>
        <pubmed_id>7531353</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. Epub 2008 Jun 10.</reference_text>
        <pubmed_id>18542932</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39.</reference_text>
        <pubmed_id>11132243</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10.</reference_text>
        <pubmed_id>7691623</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotoxine</name>
        <accession>HMDB15404</accession>
      </metabolite>
      <reference>
        <reference_text>Markstein R: Hydergine: interaction with the neurotransmitter systems in the central nervous system. J Pharmacol. 1985;16 Suppl 3:1-17.</reference_text>
        <pubmed_id>2869188</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotoxine</name>
        <accession>HMDB15404</accession>
      </metabolite>
      <reference>
        <reference_text>Korneyev AY, Cincotta AH: Identification of hepatic, non-monoamine, dihydroergocryptine binding sites with significant gender differences. Life Sci. 1996;58(12):241-8.</reference_text>
        <pubmed_id>8786706</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bevantolol</name>
        <accession>HMDB15409</accession>
      </metabolite>
      <reference>
        <reference_text>Shiraishi K, Moriya M, Miyake N, Takayanagi I: Alpha 1-adrenoceptor blocking activities of bevantolol hydrochloride(NC-1400) and labetalol in rat isolated thoracic aorta--do they distinguish between subtypes? Gen Pharmacol. 1992 Sep;23(5):843-5.</reference_text>
        <pubmed_id>1358746</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ephedrine</name>
        <accession>HMDB15451</accession>
      </metabolite>
      <reference>
        <reference_text>Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, Khan IA, Feller DR: Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes. J Pharmacol Exp Ther. 2007 Jul;322(1):214-21. Epub 2007 Apr 3.</reference_text>
        <pubmed_id>17405867</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ephedrine</name>
        <accession>HMDB15451</accession>
      </metabolite>
      <reference>
        <reference_text>Wellman PJ, Miller DK, Ho DH: Noradrenergic modulation of ephedrine-induced hypophagia.  Synapse. 2003 Apr;48(1):18-24.</reference_text>
        <pubmed_id>12557268</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ephedrine</name>
        <accession>HMDB15451</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mephentermine</name>
        <accession>HMDB15452</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mephentermine</name>
        <accession>HMDB15452</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mephentermine</name>
        <accession>HMDB15452</accession>
      </metabolite>
      <reference>
        <reference_text>Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor.  Am Heart J. 1976 Nov;92(5):661-4.</reference_text>
        <pubmed_id>10722</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Green B, Pettit T, Faith L, Seaton K: Focus on levomepromazine.  Curr Med Res Opin. 2004 Dec;20(12):1877-81.</reference_text>
        <pubmed_id>15701205</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrimeprazine</name>
        <accession>HMDB15474</accession>
      </metabolite>
      <reference>
        <reference_text>Dahl SG, Hough E, Hals PA: Phenothiazine drugs and metabolites: molecular conformation and dopaminergic, alpha adrenergic and muscarinic cholinergic receptor binding. Biochem Pharmacol. 1986 Apr 15;35(8):1263-9.</reference_text>
        <pubmed_id>2870716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dextroamphetamine</name>
        <accession>HMDB15516</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dextroamphetamine</name>
        <accession>HMDB15516</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phendimetrazine</name>
        <accession>HMDB15519</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phendimetrazine</name>
        <accession>HMDB15519</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phendimetrazine</name>
        <accession>HMDB15519</accession>
      </metabolite>
      <reference>
        <reference_text>Bray GA: Drug Insight: appetite suppressants.  Nat Clin Pract Gastroenterol Hepatol. 2005 Feb;2(2):89-95.</reference_text>
        <pubmed_id>16265126</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phendimetrazine</name>
        <accession>HMDB15519</accession>
      </metabolite>
      <reference>
        <reference_text>Bray GA: A concise review on the therapeutics of obesity.  Nutrition. 2000 Oct;16(10):953-60.</reference_text>
        <pubmed_id>11054601</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phendimetrazine</name>
        <accession>HMDB15519</accession>
      </metabolite>
      <reference>
        <reference_text>Rothman RB, Baumann MH: Therapeutic potential of monoamine transporter substrates.  Curr Top Med Chem. 2006;6(17):1845-59.</reference_text>
        <pubmed_id>17017961</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acepromazine</name>
        <accession>HMDB15552</accession>
      </metabolite>
      <reference>
        <reference_text>Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat.  Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4.</reference_text>
        <pubmed_id>15695070</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thioproperazine</name>
        <accession>HMDB15559</accession>
      </metabolite>
      <reference>
        <reference_text>Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat.  Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4.</reference_text>
        <pubmed_id>15695070</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zuclopenthixol</name>
        <accession>HMDB15561</accession>
      </metabolite>
      <reference>
        <reference_text>Khalifa AE: Zuclopenthixol facilitates memory retrieval in rats: possible involvement of noradrenergic and serotonergic mechanisms. Pharmacol Biochem Behav. 2003 Jul;75(4):755-62.</reference_text>
        <pubmed_id>12957216</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sertindole</name>
        <accession>HMDB15618</accession>
      </metabolite>
      <reference>
        <reference_text>Lindstrom E, Levander S: Sertindole: efficacy and safety in schizophrenia.  Expert Opin Pharmacother. 2006 Sep;7(13):1825-34.</reference_text>
        <pubmed_id>16925508</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sertindole</name>
        <accession>HMDB15618</accession>
      </metabolite>
      <reference>
        <reference_text>Hietala J, Kuonnamaki M, Palvimaki EP, Laakso A, Majasuo H, Syvalahti E: Sertindole is a serotonin 5-HT2c inverse agonist and decreases agonist but not antagonist binding to 5-HT2c receptors after chronic treatment. Psychopharmacology (Berl). 2001 Sep;157(2):180-7.</reference_text>
        <pubmed_id>11594443</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL: Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505.</reference_text>
        <pubmed_id>11482743</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Bishop MJ: Recent advances in the discovery of alpha1-adrenoceptor agonists.  Curr Top Med Chem. 2007;7(2):135-45.</reference_text>
        <pubmed_id>17266602</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Du L, Li M: Modeling the interactions between alpha(1)-adrenergic receptors and their antagonists. Curr Comput Aided Drug Des. 2010 Sep;6(3):165-78.</reference_text>
        <pubmed_id>20412040</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Lachnit WG, Tran AM, Clarke DE, Ford AP: Pharmacological characterization of an alpha 1A-adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat. Br J Pharmacol. 1997 Mar;120(5):819-26.</reference_text>
        <pubmed_id>9138687</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Droxidopa</name>
        <accession>HMDB15627</accession>
      </metabolite>
      <reference>
        <reference_text>Burt RP, Chapple CR, Marshall I: The role of diacylglycerol and activation of protein kinase C in alpha 1A-adrenoceptor-mediated contraction to noradrenaline of rat isolated epididymal vas deferens. Br J Pharmacol. 1996 Jan;117(1):224-30.</reference_text>
        <pubmed_id>8825367</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Xylometazoline</name>
        <accession>HMDB15640</accession>
      </metabolite>
      <reference>
        <reference_text>Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91.</reference_text>
        <pubmed_id>8894610</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Xylometazoline</name>
        <accession>HMDB15640</accession>
      </metabolite>
      <reference>
        <reference_text>Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline.  Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi:       10.1111/j.1472-8206.2009.00805.x.</reference_text>
        <pubmed_id>20030735</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isometheptene</name>
        <accession>HMDB15651</accession>
      </metabolite>
      <reference>
        <reference_text>Valdivia LF, Centurion D, Perusquia M, Arulmani U, Saxena PR, Villalon CM: Pharmacological analysis of the mechanisms involved in the tachycardic and vasopressor responses to the antimigraine agent, isometheptene, in pithed rats. Life Sci. 2004 May 14;74(26):3223-34.</reference_text>
        <pubmed_id>15094323</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isometheptene</name>
        <accession>HMDB15651</accession>
      </metabolite>
      <reference>
        <reference_text>Parker EM, Cubeddu LX: Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J Pharmacol Exp Ther. 1988 Apr;245(1):199-210.</reference_text>
        <pubmed_id>3129549</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonordefrin</name>
        <accession>HMDB15652</accession>
      </metabolite>
      <reference>
        <reference_text>Jastak JT, Yagiela JA: Vasoconstrictors and local anesthesia: a review and rationale for use.  J Am Dent Assoc. 1983 Oct;107(4):623-30.</reference_text>
        <pubmed_id>6355236</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonordefrin</name>
        <accession>HMDB15652</accession>
      </metabolite>
      <reference>
        <reference_text>Hersh EV, Giannakopoulos H: Beta-adrenergic blocking agents and dental vasoconstrictors.  Dent Clin North Am. 2010 Oct;54(4):687-96.</reference_text>
        <pubmed_id>20831932</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonordefrin</name>
        <accession>HMDB15652</accession>
      </metabolite>
      <reference>
        <reference_text>Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91.</reference_text>
        <pubmed_id>8894610</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonordefrin</name>
        <accession>HMDB15652</accession>
      </metabolite>
      <reference>
        <reference_text>Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline.  Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi:       10.1111/j.1472-8206.2009.00805.x.</reference_text>
        <pubmed_id>20030735</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naphazoline</name>
        <accession>HMDB15656</accession>
      </metabolite>
      <reference>
        <reference_text>Bogacka E: [Decongestants in treatment of nasal obstruction].  Otolaryngol Pol. 1999;53(3):347-52.</reference_text>
        <pubmed_id>10481510</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naphazoline</name>
        <accession>HMDB15656</accession>
      </metabolite>
      <reference>
        <reference_text>Leonardi A: Emerging drugs for ocular allergy.  Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.</reference_text>
        <pubmed_id>16083326</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naphazoline</name>
        <accession>HMDB15656</accession>
      </metabolite>
      <reference>
        <reference_text>Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I1-imidazoline binding sites and the high affinity state of alpha-2 adrenoceptor subtypes. J Pharmacol Exp Ther. 1996 Nov;279(2):694-702.</reference_text>
        <pubmed_id>8930173</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naphazoline</name>
        <accession>HMDB15656</accession>
      </metabolite>
      <reference>
        <reference_text>Hrometz SL, Edelmann SE, McCune DF, Olges JR, Hadley RW, Perez DM, Piascik MT: Expression of multiple alpha1-adrenoceptors on vascular smooth muscle: correlation with the regulation of contraction. J Pharmacol Exp Ther. 1999 Jul;290(1):452-63.</reference_text>
        <pubmed_id>10381812</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naphazoline</name>
        <accession>HMDB15656</accession>
      </metabolite>
      <reference>
        <reference_text>Kai T: [Effects of topical alpha 1- and beta 2-adrenoceptor stimulants on nasal nitric oxide level]. Nihon Jibiinkoka Gakkai Kaiho. 1999 Jul;102(7):898-906.</reference_text>
        <pubmed_id>10459292</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naphazoline</name>
        <accession>HMDB15656</accession>
      </metabolite>
      <reference>
        <reference_text>Ogidigben MJ, Chu TC, Potter DE: Naphazoline-induced suppression of aqueous humor pressure and flow: involvement of central and peripheral alpha(2)/I(1) receptors. Exp Eye Res. 2001 Mar;72(3):331-9.</reference_text>
        <pubmed_id>11180982</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
